PEDIATRICO MG · ALXN1210-MG-319
Public neurological clinical research study information. Check the current recruitment status in the live Wix study record.
A Phase 3, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants (6 to < 18 years of age) with Generalized Myasthenia Gravis (gMG). EudraCT 2022-501882-29-00
Sponsor: ALEXION
Phase: III
Area: Neuromuscular disorders